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The Δ6-desaturase (Δ6D), also known as fatty acid desaturase 2, is a regulatory enzyme in de novo fatty acid synthesis, which has
been linked to obesity and diabetes. The aim of the present study was to investigate the effect of peroxisome proliferative-activated
receptor 𝛿 (PPAR𝛿) agonist and MEK/ERK1/2-dependent pathway on the expression of Δ6D in human pancreatic carcinoma cell
line PANC-1. PANC-1 cells cultured in RPMI-1640 were exposed to the commonly used ERK1/2 pathway inhibitor PD98059 and
PPAR𝛿 agonist GW0742. Changes in mRNA and protein expression of Δ6D were then determined using real-time RT-PCR and
Western blot, respectively. The expression of Δ6D (𝑃 < 0.01) increased following treatment with PPAR𝛿 agonist both at mRNA
and protein levels, whereas no significant change was observed after treatment with MEK/ERK1/2 pathway inhibitor. It was also
found that the increase in the expression of Δ6D in response to GW0742 was significantly inhibited by PD98059 (>40%, 𝑃 < 0.05)
or EGF receptor-selective inhibitor AG1478 (>25%, 𝑃 < 0.05) pretreatment. PPAR𝛿 and MEK/ERK1/2 signaling pathways affect
differentially the expression of Δ6D in pancreatic cancer cells. Furthermore, there may be an inhibitory crosstalk between these
two regulatory pathways on the mRNA expression of Δ6D and subsequently on Δ6D protein expression.
1. Introduction
Numerous in vitro and in vivo studies indicate the critical
role of fatty acids in cell membrane fluidity, which in turn
affect ligand binding and cellular signal transduction of
surface receptors and G-proteins [1–3]. This role has been
demonstrated by the fact that the altered levels of fatty
acid desaturase enzymes are associated with various human
diseases like diabetes and atherosclerosis [4, 5]. Studies have
shown that lipotoxicity of human pancreatic islets, which is
attributed to accumulation of saturated fatty acids, is one of
the important causes of dysregulated insulin secretion and
apoptosis of pancreatic 𝛽-cell [6, 7]. In contrast to saturated
fatty acids, unsaturated fatty acids play a key role in survival
of the pancreatic 𝛽-cell [8, 9].Themembrane-bound enzyme
Δ6 fatty acid desaturase (Δ6D), encoded by the fatty acid
desaturase 2 (FADS2) gene, is the first and rate-limiting
enzyme in the synthesis of unsaturated fatty acids. FADS2-
deficient mouse model has revealed that Δ6D is the main
enzyme in in vivo production of n-6 polyunsaturated fatty
acids (PUFA) [10].
The delta isoform of the peroxisome proliferator-acti-
vated receptor (PPAR) 𝛿 is a family of nuclear receptors
regulating the expression of genes involved in fatty acid
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metabolism. Previous studies have reported that both PUFA
and PPAR𝛼 agonist response elements are present in the
FADS2; however, no exact region that responds indepen-
dently to PPAR𝛿 has yet been identified [11]. A high affinity
synthetic PPAR𝛿 agonist has been shown to modulate fatty
acid metabolic pathways, particularly those involving n-6
PUFAdesaturation [12].However, the exact functional targets
in these pathways have also not yet been detected.
PPAR𝛿 like other nuclear receptors may be affected by
other signaling pathways, and this crosstalk might modulate
the activity of these kinds of receptors. We recently demon-
strated that the mitogen-activated protein kinase (MAPK)
MEK/ERK1/2 signaling inhibition could alter the expression
level of Δ6D in hepatocellular carcinoma cell line HepG2
[13]. It has previously been shown that inhibition of ERK1/2
signaling had no apparent effect on PPAR𝛿 agonist-mediated
increase in glucose uptake in cultured human skeletalmuscle,
whereas PPAR𝛿 agonist increased both phosphorylation and
expression of ERK 1/2[14].Thus, it is possible that both Erk1/2
signaling and PPAR𝛿 are involved in a crosstalk contributing
to the regulation of Δ6D expression.
Several lines of evidence suggest that PPAR𝛿 activity and
Erk1/2 signaling play important role in the regulation of
pancreatic 𝛽-cells function. In the present study in human
pancreatic carcinoma cell line PANC-1, Δ6D expression was
tested for responsiveness to the synthetic PPAR𝛿 agonist
GW0742, under either MEK/ERK1/2 or epidermal growth
factor receptor (EGFR) signaling pathway blockade.
2. Materials and Methods
2.1. Materials. Cell culture materials, media, and FBS were
obtained from Sigma Chemicals Company (St. Louis, Mo,
USA). GW0742 and PD98059 were purchased from Cayman
Chemicals (Ann Arbor, MI, USA). PANC-1 cell line was
obtained from the Pasteur Institute Culture Collection in
Tehran, Iran. All other chemicals used were of analytical
grade.
2.2. Cell Culture. PANC-1 cells were grown in RPMI1640
containing 10% FBS, L-glutamine (2mM), penicillin (100
units/mL), and streptomycin (100 𝜇g/mL) at 37∘C, 5% CO
2
/
95% humidity.The subcultures with less than 8 passages were
used for drug treatment experiments. The cells were seeded
at a density of 2 × 105/well in a 6-well plate. After allowing
the cells to attach overnight, the medium was replaced with
fresh medium containing ±PPAR𝛿 agonist GW0742, specific
inhibitor of the MEK/ERK1/2 PD98059, or selective inhibitor
of EGFRAG1478. Following 48 h incubation, culturemedium
was removed; the cell monolayer was washed and collected
for mRNA and protein expression analysis.
2.3. Real-Time RT-PCR Analysis. Total RNAs were purified
with QIAamp RNA mini kit with a DNase I treatment
(Qiagen GmbH, Hilden, Germany) according to the man-
ufacturer’s instructions. Total RNAs were then resuspended
in 50 𝜇L of RNase-free water and stored at –80∘C. For
cDNA synthesis, RNA (1𝜇g) was reverse transcribed with
a first-strand cDNA synthesis kit for reverse-transcription
polymerase chain reaction (RT-PCR; Roche, Hertfordshire,
UK).
FADS2 primers [15] for real-time PCR were designed to
amplify a segment in the cDNA sequence as follows: forward
primer TTACAACATCACCAAATGGTCCAT, the intron-
spanning reverse primer GAAGGCATCCGTTGCATCTT,
and the labeled probe CCAGCGGGTCATCGGGCACTAC.
The TaqMan probes were labeled with a reporter dye (FAM)
on its 5󸀠 end and a quencher dye (TAMRA) on its 3󸀠
end. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNAwasmeasured using the predeveloped TaqManAssay.
Real-time PCR reactions were performed on an Applied
Biosystems StepOnePlus Real-Time PCR System according
to the standard protocols of the manufacturer. Samples were
assayed in triplicates.
Quantification was performed according to the relative
standard curve method described in the PE User bulletin
no. 2. Quantity of FADS2 mRNA was divided by GAPDH
mRNA content, and the normalized quantity expressed as a
unitless number, and all quantities are expressed as an x-fold
difference relative to a calibrator.
2.4. Western Blot Analysis. Cells were washed twice with PBS
and placed in lysis buffer containing antiprotease cocktail
(Roche Diagnostics, IN, USA). Protein concentration in the
supernatant of lysed cells was measured using Bradford’s
colorimetric method with reference to BSA standards (Bio-
Rad). Western blot analysis was performed according to the
standard procedures (Bio-Rad, Richmond, CA,USA). Briefly,
30 𝜇g of whole cell extract was separated by SDS PAGE. After
electrotransfer to Immobilon-P membrane (Millipore, Bed-
ford, MA, USA), the blots were blocked with 3% skim milk
and subjected to Western blot analysis with either polyclonal
anti-Δ6D or anti-𝛽-actin (Abcam, Cambridge, MA, USA).
Immunoreactive bands were detected by enhanced ECL
(Amersham Bioscience). For quantification, the developed
films were scanned and pixel intensity of Δ6D signal was
normalized against 𝛽-actin for each sample.
2.5. Statistical Analyses. Data are presented as mean ± SE.
Experiments were repeated three times in duplicate. Statisti-
cally significant differences in mean values between groups
were assessed by ANOVA test with post hoc Tukey’s test
for multiple comparisons. A 𝑃 value < 0.05 was considered
statistically significant. All analyses were carried out using
SPSS for windows version 11.0 (SPSS Inc., Chicago, IL, USA).
3. Results
To define if there is a connection between PPAR𝛿 and ERK1/2
MAPK signaling pathway on the expression of Δ6D enzyme,
PANC-1 cells were treated with a specific PPAR𝛿 agonist
(GW0742), a selective inhibitor ofMAPkinase (PD98059), or
a EGF receptor-selective tyrosine kinase inhibitor (AG1478).
To optimize the assay, cultured PANC-1 cells were incu-
bated with different concentrations of GW0742 (0–20𝜇M),
PD98059 (0–40 𝜇M), or AG1478 (0–10 𝜇M) 48 h at 37∘C
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Figure 1: Effects of different doses of the PPAR𝛿 agonist, selective inhibitor of MEK/ERK1/2, and EGF receptor-selective tyrosine kinase
inhibitor onmRNA expression ofΔ6-desaturase (Δ6D) in PANC-1 human pancreatic tumor cells. Cells were treated with GW0742, PD98059,
or AG1478 as indicated. One microgram of extracted RNA was reverse transcribed, and real-time RT-PCR to amplify Δ6 desaturase
and GAPDH cDNA fragments was performed as described. Relative expression with duplicate samples is given and was calculated by
normalization to GAPDH and represented as mean ± SE from 3 independent experiments. Data are means ± SE, 𝑛 = 3. ∗∗: 𝑃 < 0.01 for
Student’s 𝑡-test.
(Figure 1). At 1 𝜇M concentration, GW0742 induced no
apparent effect on Δ6D mRNA expression. At 10–20 𝜇M
of GW0742, Δ6D expression was significantly upregulated
(>4.3-fold, 𝑃 < 0.01) in PANC-1 cells. The treatment with all
three doses of PD98059 and AG1478 induced no significant
changes in the mRNA expression of Δ6D compared with that
of the control.
The selected doses were then studied on the both mRNA
and protein expression of Δ6D simultaneously (Figures 2
and 3). Similarly, treatment of PANC-1 cell cultures with
GW0742 significantly increased the protein expression level
of Δ6D (2.2-fold, 𝑃 < 0.01). There was also no significant
effect on cellular Δ6D protein expression following PD98059
incubation (Figure 3). Comparison of control with the com-
bined drug condition showed a significant increase only in
the mRNA expression of Δ6D (2.7-fold, 𝑃 = 0.02). It was
also found that the increase in expression of Δ6D in response
to the PPAR𝛿 agonist was significantly inhibited (>40%,
𝑃 = 0.032) by PD98059 pretreatment. EGF receptor-selective
inhibitor AG1478 also significantly reduced stimulatory effect
of GW0742 on mRNA (26%, 𝑃 = 0.032) and protein (32%,
𝑃 = 0.032) expression of Δ6D. However, the inhibitory
effect of AG1478 at the protein level was very modest when
compared to the PD98059.
4. Discussion
Regulation of carbohydrate and lipid metabolism in response
to the glucose consumption is mediated by insulin secretion
from pancreatic 𝛽-cells [16]. Several previous studies in
pancreatic islets and glucose-induced beta-(INS-1)-cell have
shown that fatty acids could modulate insulin resistance
[17–19] by inducing a number of unique responses such
as resistance to cytokine-induced 𝛽-cell destruction, altered
insulin gene expression, and controlling proinflammatory
mediators derived from n-6 PUFAs [20]. In a previous study,
we suggested that Δ6D may act as potential mediator of the
effects of ERK1/2 signaling on hepatic fatty acid composition
[13]. Kra¨mer et al.[14] have reported that PPAR𝛿 agonists
could increase phosphorylation and expression of MAPK
ERK1/2 by 2.2-fold. According to this evidence, it seems
that MAPK cascade signaling could be modulated by PPAR𝛿
activity.
In this study, it was demonstrated that PPAR𝛿 agonist
GW0742 could markedly increase Δ6D gene and protein
expression in pancreatic carcinoma cell line PANC-1. Accord-
ingly, Roberts et al. [12] have shown that PPAR𝛿 agonist
could increase unsaturated fatty acid products of the Δ6D
in liver, skeletal muscle, blood serum, and white adipose
tissue from obese mice. These results confirm an earlier
study which has shown that FADS2may contain peroxisome
proliferator response elements which are under positive
control of peroxisome proliferators [11].
In the study by Cohen [21] and colleagues, it has been
shown that PPAR𝛿 and PUFA play a key role in insulin
secretion from isolated islet cells and INS-1E. According
to this study, high glucose level in islet cell could increase
the release of n-6 PUFA, which acts as endogenous ligand
for PPAR𝛿. According to our present findings, it is thus
possible that the PPAR𝛿-mediated general response of 𝛽-
cell to increased glucose level is coupled to the production
of unsaturated fatty acids via enzymatic Δ6 desaturation.
Taken together, these results signify the role of PPAR𝛿 andΔ6
fatty acid desaturation in potency of insulin secretion from
pancreatic 𝛽-cell.
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Figure 2: Effects of the PPAR𝛿 agonist, selective inhibitor of
MEK/ERK1/2, and EGF receptor-selective tyrosine kinase inhibitor
on mRNA expression of Δ6-desaturase (Δ6D) in PANC-1 human
pancreatic tumor cells. Cells were treated with GW0742, PD98059,
or AG1478 as indicated. One microgram of extracted RNA was
reverse transcribed, and real-time RT-PCR to amplifyΔ6 desaturase
andGAPDH cDNA fragments was performed as described. Relative
expression with duplicate samples is given and was calculated by
normalization to GAPDH and represented as mean ± SE from 3
independent experiments. ∗ and ∗∗: 𝑃 < 0.05 and 𝑃 < 0.01 for
Student’s 𝑡-test, respectively.
Our findings on PANC-1 cultures incubated with MEK/
ERK1/2 inhibitor PD98059 showed no apparent change in
Δ6D mRNA and protein expression compared to untreated
control cells. In contrast with these observations, our results
in human hepatoblastoma (HepG2) cells indicated that the
expression level of Δ6D was significantly increased in the
presence of MEK/ERK1/2 inhibitor. The differences in our
results may be due to either a cell-type-specific effect or
different sensitivities in methods of measurement and use of
relative RT-PCR versus real-time RT-PCR.
We also demonstrated that treatment with both ERK1/2
inhibitor and EGFR inhibitor remarkably downregulated
GW0742-induced Δ6D mRNA and protein expression. In
spite of comparable levels of Δ6D mRNA expression, EGFR
inhibitor had less suppressive effect on PPAR𝛿 agonist-
mediated induction of Δ6D protein expression than ERK1/2
inhibitor.This differencemay be related to additional changes
in associated downstream signaling pathways, like PI3K-Akt
[22, 23]. So it could be hypothesized that there is increased
protein stability or decreased protein degradation in response
to inhibition of PI3K, which is downstream of EGFR. Slowed
EGF-induced protein degradation following inhibition of
PI3K signaling has previously been reported [24].
To the best of our knowledge, this study is the first study
to examine the combined effect of PPAR𝛿 agonist and ERK1/2
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Figure 3: Effects of the PPAR𝛿 agonist, selective inhibitor of
MEK/ERK1/2, and EGF receptor-selective tyrosine kinase inhibitor
on protein expression of Δ6-desaturase (Δ6D) in PANC-1 human
pancreatic tumor cells. Cells were treated with GW0742, PD98059,
or AG1478 as indicated. Cell lysates were analyzed for Δ6 desaturase
and 𝛽-actin. Molecular weight markers are shown. Δ6 desaturase
levels were detected by Western blots, quantified, normalized to 𝛽-
actin, and represented as mean ± SE from 3 independent exper-
iments. ∗ and ∗∗: 𝑃 < 0.05 and 𝑃 < 0.01 for Student’s 𝑡-test,
respectively.
blockade on the gene and protein expression of fatty acid
Δ6D. We used PANC-1 pancreatic tumor cells which are
well-characterized human-derived cells for studying human
pancreatic cells in vitro [25]. Based on our result, we could
conclude that EGFR signaling pathways maybe involved in
the suppression of Δ6D expression; however, the relationship
between this pathway and PPAR𝛿 remains to be investigated.
5. Conclusions
Our study showed that PPAR𝛿 and ERK1/2 MAPK signaling
pathways affect the gene expression ofΔ6D in pancreatic car-
cinoma cell line PANC-1. Furthermore, a possible inhibitory
effect of ERK1/2 MAPK signaling on PPAR𝛿 activity may
serve to coordinate Δ6 desaturation of fatty acids in pancre-
atic cells.
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